Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - HN6
HN6 Details
Status: Closed 
Activation Date: 2008DEC18
Closing Date: 2011NOV07
Phase: III 

Description: A Phase III Study Of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab In Patients With Locally Advanced Stage III And IV Squamous Cell Carcinoma Of The Head And Neck.  

Eligibility: Patients with histologically confirmed squamous cell carcinoma of the head and neck of the oral cavity, oropharynx, larynx or hypopharynx which is locally advanced as defined by TanyN+M0 or T3-4N0M0. 

Objective: The primary objective is progression free survival. The secondary objectives include: overall survival, local progression free survival, regional progression free survival, distant metastasis, acute and late adverse events, quality of life, swallowing related quality of life, functional swallowing outcome (selected centres), significance of tissue and blood biomarkers, and health economics. 

Participation: Open to member centres 

Lay Description: The purpose of this study is to compare the effects of accelerated radiotherapy with the drug panitumumab compared to standard radiotherapy with cisplatin chemotherapy. This research is being done because panitumumab and accelerated radiotherapy are promising treatments for head and neck cancer. We do not know if this may be better, the same, or worse at controlling the cancer than standard treatment. Panitumumab is a type of antibody therapy which acts against a protein on tumour cells called the epidermal growth factor receptor. Panitumumab belongs to a class of drugs call "EGFR inhibitors". Other EGFR inhibitors similar to panitumumab have been shown to slow the growth of head and neck cancer when combined with radiotherapy. Panitumumab has been shown to slow the growth of advanced colon cancer.  

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
HEAD AND NECK HN6 320 142 89 208
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
HEAD AND NECK HN6 320 2 16
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
HEAD AND NECK HN6 320 1 263 0 0 263 266 0 0